CVVT

Researchers at the AIDS Institute and Department of Microbiology, School of Clinical Medicine, LKS Faculty of Medicine of The University of Hong Kong (HKUMed) and the Center for Virology, Vaccinology and Therapeutics (CVVT) have invented a tandem bispecific antibody, M-SiaB. The invention involves a sialic acid-receptor anchoring strategy, which significantly enhances the potency and breadth of M-SiaB against not only diverse subtypes of influenza viruses (e.g. H1N1, H3N2, H5N1 and H7N9) in...

Last week, the global healthcare community gathered in Hong Kong for the prestigious 6th Asia Summit on Global Health (ASGH) 2026. Jointly organised by the HKSAR Government and the Hong Kong Trade Development Council (HKTDC), the summit operated under the theme "Fuelling Healthcare Breakthroughs". As a leader in medical innovation, CVVT was proud to play a role in this flagship event, which drew 3,000 participants from 43 countries to explore the future of the global healthcare ecosystem. ...

In the press conference of 12 February 2026, Professor KY Yuen in his capacity as the Director of the Centre of Virology, Vaccinology and Therapeutics (CVVT) delivered an academic talk about a novel scientific approach which leads to the discovery of compounds or extracts which inhibit the release of toxin by Staphylococcus aureus without killing the bacteria. This approach would reduce the risk of induction of antibiotic resistance and disruption of the normal microbiome of human. Prof Yuen...